ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
November 06 2023 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo
Acoustic Enhanced UltraSound (TAEUS®), today announced it will host
an offsite panel discussion with multidisciplinary experts during
the American Association for the Study of Liver Diseases (AASLD)
annual meeting, The Liver Meeting, taking place November 10-14,
2023, in Boston. The panel will feature three key opinion leaders
(KOLs) in the fields of hepatology, endocrinology and radiology
sharing their unique perspectives on managing Metabolic-Associated
Steatotic Liver Disease (MASLD).
The KOL panelists will include:
- Raza Malik, M.D., Ph.D., FRCP, FAASLD, Chief of Hepatology at
Lahey Hospital and Medical Center
- Christos Mantzoros, MD., DSc, Ph.D., Chief of Endocrinology,
Diabetes and Metabolism at the Boston VA Healthcare System, and
Professor of Medicine at Harvard Medical School
- Jing Gao, M.D., FAIUM, Professor of Ultrasound at Rocky Vista
University, and Adjunct Professor of Research in Radiology at Weill
Cornell Medicine
The invitation-only clinical discussion will be moderated by
ENDRA, and the opinions expressed are those of the independent KOL
participants and not of ENDRA or the KOLs’ institutions.
“We are delighted to be attending the prestigious AASLD The
Liver Meeting and contributing to the topical discussion of early
detection and management of MASLD. The assembled panel of
multidisciplinary experts are highly respected in their respective
fields and will provide diverse perspectives on the management of
this disease today and in the future,” stated Francois Michelon,
Chairman and Chief Executive Officer of ENDRA.
“With the near-term prospect of therapeutics for treating
steatotic liver disease coming to market, there is a pressing
clinical need for a non-invasive and cost-effective tool to screen
and monitor patients,” he added. “We believe this provides a
tremendous opportunity for ENDRA's technology, which has the
ability to assess liver fat at the point-of-patient care and may
potentially help improve the health of millions of people.”
ENDRA will also be showcasing its TAEUS technology at The Liver
Meeting in booth #2801 in Exhibit Hall D at the Hynes Convention
Center. The TAEUS device has a De Novo request under review with
the U.S. Food and Drug Administration and is not currently
available for sale in the United States.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 700,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Steatotic Liver Disease (SLD) (formerly known
as NAFLD-NASH), a chronic liver spectrum that affects over two
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including visualization of
tissue temperature during energy-based surgical procedures. For
more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “forecast,” “future,” "goal,"
“hope,” "intend," "may," "plan," “possible,” “potential,”
“project,” "seek," "should," "will," “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing for receipt of
required regulatory approvals and product launches; future
financial position and projected costs and revenue; expectations
concerning ENDRA's business strategy; ENDRA’s ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; and ENDRA’s ability to protect its intellectual property.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others: the ability to raise additional capital in
order to continue as a going concern; the ability to obtain
regulatory approvals necessary to sell ENDRA medical devices in
certain markets in a timely manner, or at all; the ability to
develop a commercially feasible technology and its dependence on
third parties to design and manufacture its products; the impact of
COVID-19 on ENDRA’s business plans; the ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission. You should
not rely upon forward-looking statements as predictions of future
events. The forward-looking statements made in this press release
speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106229465/en/
Contacts: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com Investor Relations:
Yvonne Briggs LHA Investor Relations (310) 691-7100
YBriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From May 2024 to Jun 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Jun 2023 to Jun 2024